Interval between secondary cytoreductive surgery and adjuvant chemotherapy is not associated with survivals in patients with recurrent ovarian cancer

BACKGROUND: Secondary cytoreductive surgery (SCS) is possible in selected patients with recurrent epithelial ovarian cancer (EOC). The goal of SCS is complete resection, although chemotherapy is always followed. Delayed intervals between primary debulking surgery and adjuvant chemotherapy was report...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Ovarian Res
Hlavní autoři: Jeong, Soo Young, Choi, Chel Hun, Kim, Tae Joong, Lee, Jeong Won, Kim, Byoung-Gie, Bae, Duk Soo, Lee, Yoo-Young
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2019
Témata:
Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6937657/
https://ncbi.nlm.nih.gov/pubmed/31892329
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13048-019-0602-5
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky